title: Invasive ductal breast carcinoma with predominant intraductal component: Clinicopathological features and prognosis.
abstract: OBJECTIVE
  Invasive ductal carcinoma with predominant intraductal component (IDCPIC) represents almost 5% of breast cancers. Nevertheless few data exist concerning their characteristics and prognostic behaviour. Our objective was to describe IDCPIC's clinicopathological and prognostic features and compare them to that of invasive ductal carcinoma without predominant intraductal component (IDC).
  
  
  METHODS
  Retrospective single centre study including all the localized invasive ductal carcinoma listed in our institutional database. Clinical, radiological and pathological criteria were collected as well as disease-free survival (DFS) data.
  
  
  RESULTS
  From 1995 to 2008, 4109 invasive ductal breast cancers treated were included. Out of them 192 (4.7%) were IDCPIC. Most of IDCPIC (63%) were discovered by radiological screening whereas IDC suspicion was more often clinical (82.7% vs 49.5%, p < 0.001). Pathological lymph node involvement was less frequent in IDCPIC (35.8 vs 44.3%, p = 0.04). Invasive tumour median size was 2-fold smaller in IDCPIC (10 mm vs 20 mm, p<0.001). Hormone receptors expression was similar between both groups whereas HER2 overexpression was more frequent in IDCPIC (32% vs 14.3%, p<0.001). Mastectomy was more frequently performed for IDCPIC (67.7% vs 30.3%, p < 0.001) whereas chemotherapy and radiation therapy were less frequent (55.5% vs 68%, and 82.8% vs 95.5%, respectively, p < 0.001 for both). After matching for discriminant clinicopathological features (tumour size, lymph node involvement, vascular invasion, HER2), DFS was similar in both groups (5-year DFS of 87.4% vs 84.4%, p = 0.47).
  
  
  CONCLUSIONS
  IDCPIC and other IDC with invasive components showing similar clinicopathological features display a similar prognosis.
authors.affiliation: Department of Oncology, Institut Paoli-Calmettes, Marseille, France; Centre de Recherche en Cancérologie de Marseille, INSERM U1068, CNRS U7258, Marseille, France; Aix-Marseille Université, Marseille, France.
authors.forename: Renaud
authors.initials: R
authors.lastname: Sabatier
authors.affiliation: Aix-Marseille Université, Marseille, France; Department of Surgical Oncology, Institut Paoli-Calmettes, Marseille, France. Electronic address: laurasabiani@hotmail.com.
authors.forename: Laura
authors.initials: L
authors.lastname: Sabiani
authors.affiliation: Department of Clinical Research and Innovation, Methodology and Biostatistics Unit, Institut Paoli-Calmettes, Marseille, France.
authors.forename: Christophe
authors.initials: C
authors.lastname: Zemmour
authors.affiliation: Aix-Marseille Université, Marseille, France; Department of Biopathology, Institut Paoli-Calmettes, Marseille, France.
authors.forename: Sébastien
authors.initials: S
authors.lastname: Taix
authors.affiliation: Department of Surgical Oncology, Institut Paoli-Calmettes, Marseille, France.
authors.forename: Elisabeth
authors.initials: E
authors.lastname: Chereau
authors.affiliation: Department of Oncology, Institut Paoli-Calmettes, Marseille, France; Centre de Recherche en Cancérologie de Marseille, INSERM U1068, CNRS U7258, Marseille, France; Aix-Marseille Université, Marseille, France.
authors.forename: Anthony
authors.initials: A
authors.lastname: Gonçalves
authors.affiliation: Department of Radiology, Institut Paoli-Calmettes, Marseille, France.
authors.forename: Aurélie
authors.initials: A
authors.lastname: Jalaguier-Coudray
authors.affiliation: Centre de Recherche en Cancérologie de Marseille, INSERM U1068, CNRS U7258, Marseille, France; Aix-Marseille Université, Marseille, France; Department of Biopathology, Institut Paoli-Calmettes, Marseille, France.
authors.forename: Emmanuelle
authors.initials: E
authors.lastname: Charafe-Jauffret
authors.affiliation: Department of Radiotherapy, Institut Paoli-Calmettes, Marseille, France.
authors.forename: Michel
authors.initials: M
authors.lastname: Resbeut
authors.affiliation: Department of Oncology, Institut Paoli-Calmettes, Marseille, France.
authors.forename: Jean-Marc
authors.initials: JM
authors.lastname: Extra
authors.affiliation: Department of Oncology, Institut Paoli-Calmettes, Marseille, France; Centre de Recherche en Cancérologie de Marseille, INSERM U1068, CNRS U7258, Marseille, France; Aix-Marseille Université, Marseille, France.
authors.forename: Patrice
authors.initials: P
authors.lastname: Viens
authors.affiliation: Department of Radiotherapy, Institut Paoli-Calmettes, Marseille, France.
authors.forename: Agnès
authors.initials: A
authors.lastname: Tallet
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001943:Breast Neoplasms / Q000737:chemistry / Q000473:pathology* / Q000601:surgery; D018270:Carcinoma, Ductal, Breast / Q000737:chemistry / Q000473:pathology* / Q000601:surgery; D002285:Carcinoma, Intraductal, Noninfiltrating / Q000737:chemistry / Q000473:pathology* / Q000601:surgery; D005260:Female; D006801:Humans; D008207:Lymphatic Metastasis; D008408:Mastectomy; D008875:Middle Aged; D011379:Prognosis; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000032:analysis; D012189:Retrospective Studies; D047368:Tumor Burden
chemical_list: D018719:Erb-b2 Receptor Tyrosine Kinases; C508053:ERBB2 protein, human
keywords: Disease-free survival; HER2 overexpression; Invasive ductal carcinoma; Invasive ductal carcinoma with predominant intraductal component